Association of chronic hypertension with birth of small-for-gestational-age neonate

Objective: To examine the effect of chronic hypertension (CH), with and without superimposed preeclampsia (PE), on the incidence of small for gestational age (SGA) neonates, and explore possible mechanisms for such association.

Methods: The data for the study were derived from prospective screening for adverse pregnancy outcomes in women with singleton pregnancies attending for their first routine hospital visit at 11-13 weeks’ gestation, which included recording of maternal characteristics and medical history and measurement of mean arterial pressure (MAP). Birth weight z-score, adjusted for gestational age and for maternal and pregnancy characteristics, and incidence of SGA were compared between those with and without CH in the total population and in the subgroups with and without PE. Regression analysis was used to examine the relationship between MAP and birth weight z-score and incidence of SGA and PE in those with and without CH.

Results: The study population constituted 74,226 pregnancies, including 1,052 (1.4%) with CH and 73,174 without CH. Preeclampsia developed in 233 (22.1%) cases of the group with CH and in 1,662 (2.3%) of those without CH. In the group that developed PE, there was no significant difference between those with CH and those without CH in either the median birth weight z-score or the incidence of SGA. In the group without PE, the incidence of SGA was twice as high in those with than in those without CH. There was a significant association between log10 MAP multiple of the median and incidence of SGA and PE which was more marked in those with CH than in those without CH.

Conclusion: CH is associated with increased risk of SGA and PE and this is related to MAP at 11-13 weeks’ gestation.

1. Panaitescu AM, Syngelaki A, Prodan N, Akolekar R, Nicolaides KH. Chronic hypertension and adverse pregnancy outcome: a cohort study. Ultrasound Obstet Gynecol 2017; 50: 228–235.
2. Villar J, Carroli G, Wojdyla D, Abalos E, Giordano D, Ba’aqeel H, Farnot U, Bergsjø P, Bakketeig L, Lumbiganon P, Campod´onico L, Al-Mazrou Y, Lindheimer M, Kramer M; World Health Organization Antenatal Care Trial Research Group.
Preeclampsia, gestational hypertension and intrauterine growth restriction, related or independent conditions? Am J Obstet Gynecol 2006; 194: 921–931.
3. Robinson HP, Fleming JE. A critical evaluation of sonar crown rump length measurements. BJOG 1975; 182: 702–710.
4. Syngelaki A, Chelemen T, Dagklis T, Allan L, Nicolaides KH. Challenges in the diagnosis of fetal non-chromosomal abnormalities at 11–13 weeks. Prenat Diagn 2011; 31: 90–102.
5. Poon LC, Zymeri NA, Zamprakou A, Syngelaki A, Nicolaides KH. Protocol for measurement of mean arterial pressure at 11-13 weeks’ gestation. Fetal Diagn Ther 2012; 31: 42–48.
6. Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Moutquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement
from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001; 20:IX–XIV.
7. Poon LC, Tan MY, Yerlikaya G, Syngelaki A, Nicolaides KH. Birth weight in live births and stillbirths. Ultrasound Obstet Gynecol 2016; 48: 602–606.
8. Wright A, Wright D, Ispas A, Poon LC, Nicolaides KH. Mean arterial pressure in the three trimesters of pregnancy: effects of maternal characteristics and medical history.
Ultrasound Obstet Gynecol 2015; 45: 698–706.
9. Potthoff R. A non-parametric test of whether two simple regression lines are parallel. Ann Statist 1974; 2: 295–310.
10. Armitage P, Berry G, Matthews JNS. Statistical methods in medical research. 4th ed; 2002. Blackwell Science.
11. American College of Obstetricians and Gynecologists; Task Force on Hypertension in Pregnancy. Hypertension in pregnancy. Report of the American College of Obstetricians and Gynecologists’ Task Force on Hypertension in Pregnancy. Obstet Gynecol 2013; 122: 1122–1131.
12. NICE. Hypertension in pregnancy: The management of hypertensive disorders during pregnancy. NICE Clinical Guideline 107. Manchester, UK: National Institute for
Health and Care Excellence, 2011: 1–53.
13. von Dadelszen P, Ornstein MP, Bull SB, Logan AG, Koren G, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: a
meta-analysis. Lancet 2000; 355: 87–92.
14. von Dadelszen P, Magee LA. Fall in mean arterial pressure and fetal growth restriction in pregnancy hypertension: an updated metaregression analysis. J Obstet Gynaecol
Can 2002; 24: 941–945.
15. Abalos E, Duley L, Steyn DW. Antihypertensive drug therapy for mild to moderate hypertension during pregnancy. Cochrane Database Syst Rev 2014; 2: CD002252.
16. Magee LA, von Dadelszen P, Rey E, Ross S, Asztalos E, Murphy KE, Menzies J, Sanchez J, Singer J, Gafni A, Gruslin A, Helewa M, Hutton E, Lee SK, Lee
T, Logan AG, Ganzevoort W, Welch R, Thornton JG, Moutquin JM. Less-tight versus tight control of hypertension in pregnancy. NEnglJMed2015; 372: 407–417.
17. Caritis S, Sibai B, Hauth J, Lindheimer MD, Klebanoff M, Thom E, VanDorsten P, Landon M, Paul R, Miodovnik M, Meis P, Thurnau G. Low-dose aspirin to prevent preeclampsia in women at high risk. National Institute of Child Health and Human
Development Network of Maternal-Fetal Medicine Units. NEnglJMed1998; 338: 701–705.
18. Ankumah NA, Cantu J, Jauk V, Biggio J, Hauth J, Andrews W, Tita AT. Risk of adverse pregnancy outcomes in women with mild chronic hypertension before 20 weeks of gestation. Obstet Gynecol 2014; 123: 966–972.
19. Lee RM, Dickhout JG, Sandow SL. Vascular structural and functional changes: their association with causality in hypertension: models, remodeling and relevance. Hypertens Res 2017; 40: 311–323.
20. Burton GJ, Woods AW, Jauniaux E, Kingdom JC. Rheological and physiological
consequences of conversion of the maternal spiral arteries for uteroplacental blood
flow during human pregnancy. Placenta 2009; 30: 473–482.